Mohammed Dar becomes third MedImmune exec to join Immunocore
MedImmune’s Vice President of Clincial Development Oncology, Mohammed Dar has joined British biotech Immunocore as the company’s new CMO.
Dar is the third MedImmune executive to leave the AstraZeneca-subsidiary for Immunocore, after the head of MedImmune, Bahija Jallal, and the company’s Vice President, Translational Medicine Koustubh Ranade, joined Immunocore earlier this year.
Dar will oversee the development of the Oxford-based biotech’s leading molecule, tebentafusp which was recently granted fast track designation for Metastatic Uveal Melanoma.
Alongside its work in autoimmune and infectious diseases, the T-cell receptor (TCR) technology specialist is one of a number of companies exploring the potential of CAR-T therapies in the treatment of cancer.
Commenting on the appointment, Bahija Jallal Chief Executive Officer of Immunocore, said: “Immunocore is approaching a crucial point in the Company’s development, with our lead product candidate, tebentafusp, moving through pivotal studies. Mohammed has a complete breadth of experience in leading clinical teams through early and late stage development. We’re delighted to have such a distinguished physician, scientist and industry leader join us as we progress tebentafusp and our other promising candidates through clinical development.”
A graduate of the University of North Carolina and Duke University Medical School, Dar brings to the role more than 15 years’ worth of experience having spent long stints at MedImmune and British multinational GSK.
“The potential of Immunocore’s unparalleled science and TCR platform is very impressive,” said Mohammed Dar, Head of Clinical Development and Chief Medical Officer of Immunocore. “ Iam thrilled to have joined Immunocore at such an exciting time for the Company and I look forward to working with the scientific leadership team to drive this compelling science forward.”